TARA Key Statistics, Chart & Performance
The current stock price of TARA is 5.075 USD. In the past month the price decreased by -21.54%. In the past year, price decreased by -3.06%.
TARA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.69 | 395.65B | ||
| AMGN | AMGEN INC | 15.09 | 177.75B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.94B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.96 | 118.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.21 | 81.41B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.22 | 53.65B | ||
| INSM | INSMED INC | N/A | 37.29B | ||
| NTRA | NATERA INC | N/A | 34.07B | ||
| BIIB | BIOGEN INC | 10.89 | 26.75B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.66B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About TARA
Company Profile
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2014-10-22. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Company Info
PROTARA THERAPEUTIC INC
345 Park Avenue South, 3rd Floor
New York City NEW YORK 10010 US
CEO: Jesse Shefferman
Employees: 28
Phone: 16468440337
PROTARA THERAPEUTIC INC / TARA FAQ
What does TARA do?
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2014-10-22. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
What is the stock price of PROTARA THERAPEUTIC INC today?
The current stock price of TARA is 5.075 USD. The price decreased by -5.84% in the last trading session.
Does TARA stock pay dividends?
TARA does not pay a dividend.
How is the ChartMill rating for PROTARA THERAPEUTIC INC?
TARA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is TARA stock listed?
TARA stock is listed on the Nasdaq exchange.
Can you provide the upcoming earnings date for PROTARA THERAPEUTIC INC?
PROTARA THERAPEUTIC INC (TARA) will report earnings on 2026-03-03, after the market close.
TARA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to TARA. When comparing the yearly performance of all stocks, TARA is a bad performer in the overall market: 63.86% of all stocks are doing better.
TARA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TARA. While TARA has a great health rating, there are worries on its profitability.
TARA Financial Highlights
Over the last trailing twelve months TARA reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 48.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.58% | ||
| ROE | -39.99% | ||
| Debt/Equity | 0 |
TARA Forecast & Estimates
12 analysts have analysed TARA and the average price target is 25.5 USD. This implies a price increase of 402.46% is expected in the next year compared to the current price of 5.075.